메뉴 건너뛰기




Volumn 22, Issue 3, 2016, Pages 680-690

NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models

Author keywords

[No Author keywords available]

Indexed keywords

ALDESLEUKIN; ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; NKTR 214; STAT5 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HYBRID PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MACROGOL DERIVATIVE; NKTR-214; PRODRUG; PROTEIN BINDING; RECOMBINANT PROTEIN;

EID: 84958979893     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1631     Document Type: Article
Times cited : (306)

References (37)
  • 1
    • 84936871442 scopus 로고    scopus 로고
    • The evolving role of immune checkpointe inhibitors in cancer treatment
    • Pennock G, Chow L. The evolving role of immune checkpointe inhibitors in cancer treatment. Oncologist 2015;20:1-11.
    • (2015) Oncologist , vol.20 , pp. 1-11
    • Pennock, G.1    Chow, L.2
  • 2
    • 84859153479 scopus 로고    scopus 로고
    • Raising the bar: The curative potential of human cancer immunotherapy
    • Rosenberg SA. Raising the bar: The curative potential of human cancer immunotherapy. Sci Transl Med 2012;4:127ps8.
    • (2012) Sci Transl Med , vol.4 , pp. 127-128
    • Rosenberg, S.A.1
  • 3
  • 4
    • 48249117436 scopus 로고    scopus 로고
    • High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: A retrospective analysis of response and survival in patients treated in the surgery branch at thenationalcancer institute between 1986 and 2006
    • Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: A retrospective analysis of response and survival in patients treated in the Surgery Branch at theNationalCancer Institute between 1986 and 2006. Cancer 2008;113:293-301.
    • (2008) Cancer , vol.113 , pp. 293-301
    • Klapper, J.A.1    Downey, S.G.2    Smith, F.O.3    Yang, J.C.4    Hughes, M.S.5    Kammula, U.S.6
  • 5
    • 0033024863 scopus 로고    scopus 로고
    • Highdose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
    • Atkins MB, Lotze MT, Dutcher JP, Fisher RI,Weiss G, Margolin K, et al. Highdose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16.
    • (1999) J Clin Oncol , vol.17 , pp. 2105-2116
    • Atkins, M.B.1    Lotze, M.T.2    Dutcher, J.P.3    Fisher, R.I.4    Weiss, G.5    Margolin, K.6
  • 6
    • 0032471712 scopus 로고    scopus 로고
    • Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2-Identification of the antigens mediating response
    • Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2-Identification of the antigens mediating response. Ann Surg 1998;228:307-19.
    • (1998) Ann Surg , vol.228 , pp. 307-319
    • Rosenberg, S.A.1    Yang, J.C.2    White, D.E.3    Steinberg, S.M.4
  • 7
    • 27944505913 scopus 로고    scopus 로고
    • Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors
    • Wang X, Rickert M, Garcia KC. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science 2005; 310:1159-63.
    • (2005) Science , vol.310 , pp. 1159-1163
    • Wang, X.1    Rickert, M.2    Garcia, K.C.3
  • 8
    • 54349096567 scopus 로고    scopus 로고
    • Cytokine therapy in cancer
    • Margolin K. Cytokine therapy in cancer. Expert Opin Biol Ther 2008; 8:1495-505.
    • (2008) Expert Opin Biol Ther , vol.8 , pp. 1495-1505
    • Margolin, K.1
  • 9
    • 84857646605 scopus 로고    scopus 로고
    • The role of interleukin-2 during homeostasis and activation of the immune system
    • Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 2012;12:180-90.
    • (2012) Nat Rev Immunol , vol.12 , pp. 180-190
    • Boyman, O.1    Sprent, J.2
  • 10
    • 77749279776 scopus 로고    scopus 로고
    • PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
    • Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010;107:4275-80.
    • (2010) Proc Natl Acad Sci U S A , vol.107 , pp. 4275-4280
    • Curran, M.A.1    Montalvo, W.2    Yagita, H.3    Allison, J.P.4
  • 11
    • 84877072174 scopus 로고    scopus 로고
    • Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
    • Gajewski TF, Woo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol 2013;25:268-76.
    • (2013) Curr Opin Immunol , vol.25 , pp. 268-276
    • Gajewski, T.F.1    Woo, S.R.2    Zha, Y.3    Spaapen, R.4    Zheng, Y.5    Corrales, L.6
  • 12
    • 61349100263 scopus 로고    scopus 로고
    • B7 blockade alters the balance between regulatory T cells and tumor-reactive T cells for immunotherapy of cancer
    • Zhou P, Zheng X, Zhang H, Liu Y, Zheng P. B7 blockade alters the balance between regulatory T cells and tumor-reactive T cells for immunotherapy of cancer. Clin Cancer Res 2009;15:960-70.
    • (2009) Clin Cancer Res , vol.15 , pp. 960-970
    • Zhou, P.1    Zheng, X.2    Zhang, H.3    Liu, Y.4    Zheng, P.5
  • 13
    • 1642497640 scopus 로고    scopus 로고
    • Tumor-specific human CD4+ regulatory T cells and their ligands: Implications for immunotherapy
    • Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y, et al. Tumor-specific human CD4+ regulatory T cells and their ligands: Implications for immunotherapy. Immunity 2004;20:107-18.
    • (2004) Immunity , vol.20 , pp. 107-118
    • Wang, H.Y.1    Lee, D.A.2    Peng, G.3    Guo, Z.4    Li, Y.5    Kiniwa, Y.6
  • 16
    • 84959031419 scopus 로고    scopus 로고
    • [accessed 2015 Jun 29]. Available from
    • UC10-4F10-11 (ATCC- HB-304-) culture method; 2015 [accessed 2015 Jun 29]. Available from http://www.atcc.org/Products/All/HB-304. aspx#culturemethod.
    • (2015) UC10-4F10-11 (ATCC- HB-304-) Culture Method
  • 17
    • 33644540157 scopus 로고    scopus 로고
    • Crystal structure of the IL-2 signaling complex: Paradigm for a heterotrimeric cytokine receptor
    • Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA. Crystal structure of the IL-2 signaling complex: Paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A 2006;103:2788-93.
    • (2006) Proc Natl Acad Sci U S A , vol.103 , pp. 2788-2793
    • Stauber, D.J.1    Debler, E.W.2    Horton, P.A.3    Smith, K.A.4    Wilson, I.A.5
  • 18
    • 0028840032 scopus 로고
    • Quantitation of the renal clearance of interleukin-2 using nephrectomized and ureterligated rats
    • Gibbons JA, Luo ZP, Hannon ER, Braeckman RA, Young JD. Quantitation of the renal clearance of interleukin-2 using nephrectomized and ureterligated rats. J Pharmacol Exp Ther 1995;272:119-25.
    • (1995) J Pharmacol Exp Ther , vol.272 , pp. 119-125
    • Gibbons, J.A.1    Luo, Z.P.2    Hannon, E.R.3    Braeckman, R.A.4    Young, J.D.5
  • 20
    • 0029947568 scopus 로고    scopus 로고
    • Enhancement of antitumor immunity by CTLA-4 blockade
    • Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6.
    • (1996) Science , vol.271 , pp. 1734-1736
    • Leach, D.R.1    Krummel, M.F.2    Allison, J.P.3
  • 21
    • 42949139835 scopus 로고    scopus 로고
    • Phase i study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma
    • Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, Agarwala SS, et al. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 2008;26:2034-9.
    • (2008) J Clin Oncol , vol.26 , pp. 2034-2039
    • Thompson, J.A.1    Curti, B.D.2    Redman, B.G.3    Bhatia, S.4    Weber, J.S.5    Agarwala, S.S.6
  • 22
    • 0030005718 scopus 로고    scopus 로고
    • The role of cytokines, adhesion molecules, and chemokines in interleukin-2-induced lymphocytic infiltration in C57BL/6 mice
    • Anderson JA, Lentsch AB, Hadjiminas DJ, Miller FN, Martin AW, Nakagawa K, et al. The role of cytokines, adhesion molecules, and chemokines in interleukin-2-induced lymphocytic infiltration in C57BL/6 mice. J Clin Invest 1996;97:1952-9.
    • (1996) J Clin Invest , vol.97 , pp. 1952-1959
    • Anderson, J.A.1    Lentsch, A.B.2    Hadjiminas, D.J.3    Miller, F.N.4    Martin, A.W.5    Nakagawa, K.6
  • 23
    • 84862246130 scopus 로고    scopus 로고
    • Sylatron: A pegylated interferon for use inmelanoma
    • Patel JN,Walko CM. Sylatron: A pegylated interferon for use inmelanoma. Ann Pharmacother 2012;46:830-8.
    • (2012) Ann Pharmacother , vol.46 , pp. 830-838
    • Patel, J.N.1    Walko, C.M.2
  • 24
    • 33748918574 scopus 로고    scopus 로고
    • Nanomedicine: Clinical applications of polyethylene glycol conjugated proteins and drugs
    • Parveen S, Sahoo SK. Nanomedicine: Clinical applications of polyethylene glycol conjugated proteins and drugs. Clin Pharmacokinet 2006;45: 965-88.
    • (2006) Clin Pharmacokinet , vol.45 , pp. 965-988
    • Parveen, S.1    Sahoo, S.K.2
  • 25
    • 55749111387 scopus 로고    scopus 로고
    • The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics
    • Fishburn CS. The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008;97:4167-83.
    • (2008) J Pharm Sci , vol.97 , pp. 4167-4183
    • Fishburn, C.S.1
  • 26
    • 84919759438 scopus 로고    scopus 로고
    • Springer- Verlag, Heidelberg; New York, NY 281
    • Kunugi K, Yamaoka T. Polymers in nanomedicine. Springer-Verlag, Heidelberg; New York, NY; 2012. p.xi, 281p.
    • (2012) Polymers in Nanomedicine , pp. 11
    • Kunugi, K.1    Yamaoka, T.2
  • 27
  • 28
    • 34250689881 scopus 로고    scopus 로고
    • Phase i trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer
    • Margolin K, Atkins MB, Dutcher JP, Ernstoff MS, Smith JW, Clark JI, et al. Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. Clin Cancer Res 2007;13:3312-9.
    • (2007) Clin Cancer Res , vol.13 , pp. 3312-3319
    • Margolin, K.1    Atkins, M.B.2    Dutcher, J.P.3    Ernstoff, M.S.4    Smith, J.W.5    Clark, J.I.6
  • 29
    • 77955345138 scopus 로고    scopus 로고
    • Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
    • Krieg C, L-etourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A 2010;107:11906-11.
    • (2010) Proc Natl Acad Sci U S A , vol.107 , pp. 11906-11911
    • Krieg, C.1    L-Etourneau, S.2    Pantaleo, G.3    Boyman, O.4
  • 30
    • 79957917039 scopus 로고    scopus 로고
    • A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity
    • Gillies SD, Lan Y, Hettmann T, Brunkhorst B, Sun Y,Mueller SO, et al. A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity. Clin Cancer Res 2011;17:3673-85.
    • (2011) Clin Cancer Res , vol.17 , pp. 3673-3685
    • Gillies, S.D.1    Lan, Y.2    Hettmann, T.3    Brunkhorst, B.4    Sun, Y.5    Mueller, S.O.6
  • 31
    • 84862776988 scopus 로고    scopus 로고
    • Exploiting a natural conformational switch to engineer an interleukin-2superkine'
    • Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, Su L, et al. Exploiting a natural conformational switch to engineer an interleukin-2superkine'. Nature 2012;484:529-33.
    • (2012) Nature , vol.484 , pp. 529-533
    • Levin, A.M.1    Bates, D.L.2    Ring, A.M.3    Krieg, C.4    Lin, J.T.5    Su, L.6
  • 32
    • 84859892358 scopus 로고    scopus 로고
    • Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model
    • Sundstedt A, Celander M, Eriksson E, Torngren M, Hedlund G. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model. J Immunother 2012;35:344-53.
    • (2012) J Immunother , vol.35 , pp. 344-353
    • Sundstedt, A.1    Celander, M.2    Eriksson, E.3    Torngren, M.4    Hedlund, G.5
  • 33
    • 33745851479 scopus 로고    scopus 로고
    • CTLA4 blockade and GMCSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
    • Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GMCSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006;116:1935-45.
    • (2006) J Clin Invest , vol.116 , pp. 1935-1945
    • Quezada, S.A.1    Peggs, K.S.2    Curran, M.A.3    Allison, J.P.4
  • 34
    • 84886443514 scopus 로고    scopus 로고
    • CTLA-4 and PD-1/PD-L1 blockade: New immunotherapeutic modalities with durable clinical benefit in melanoma patients
    • Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: New immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013;19:5300-9.
    • (2013) Clin Cancer Res , vol.19 , pp. 5300-5309
    • Ott, P.A.1    Hodi, F.S.2    Robert, C.3
  • 36
    • 84860898062 scopus 로고    scopus 로고
    • The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology
    • Hafalla JC, Claser C, Couper KN, Grau GE, Renia L, De Souza JB, et al. The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology. PLoS Patholog 2012;8:e1002504.
    • (2012) PLoS Patholog , vol.8 , pp. e1002504
    • Hafalla, J.C.1    Claser, C.2    Couper, K.N.3    Grau, G.E.4    Renia, L.5    De Souza, J.B.6
  • 37
    • 84879104519 scopus 로고    scopus 로고
    • Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors
    • Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013;73: 3591-603.
    • (2013) Cancer Res , vol.73 , pp. 3591-3603
    • Duraiswamy, J.1    Kaluza, K.M.2    Freeman, G.J.3    Coukos, G.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.